Idiopathic pulmonary fibrosis: On the move

The Lancet Respiratory Medicine

Volumn 2, Issue 1, 2014, Pages 17-19

  Bouros, Demosthenes ^a   Tzouvelekis, Argyris ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; PLACEBO;

DISEASE CLASSIFICATION; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOLOGY; NOTE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT RESPONSE; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; POLYMORPHISM, GENETIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891373517     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70240-6     Document Type: Note

References (10)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013, 188:733-748.
3. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013, 45:613-620.
4. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011, 364:1503-1512.
5. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013, 309:2232-2239.
6. Noth I, Zhang Y, Ma S-F, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013, 1:309-317.
7. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013, 5:205ra136.
8. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013, 158:641-649.
9. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013, 1:369-376.
10. Tzouvelekis A, Bouros D Anti-acid treatment for idiopathic pulmonary fibrosis. Lancet Respir Med 2013, 1:348-349.